Feedback / Questions
NPX887 - NextPoint
https://www.businesswire.com/news/home/20240220381798/en/NextPoint-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1ab-Clinical-Trial-of-NPX887-a-Novel-Therapeutic-Targeting-HHLA2-to-Reactivate-Exhausted-T-and-NK-Cells-in-HHLA2-Solid-Tumors
Feb 20, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next